Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria
Overview
The purpose of this study is to determine the efficacy of pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children.
Full Title of Study: “Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Double (Investigator, Outcomes Assessor)
- Study Primary Completion Date: August 2017
Interventions
- Drug: Pyronaridine-artesunate
- Drug: Artemether-lumefantrine combination
Arms, Groups and Cohorts
- Experimental: Pyronaridine-artesunate
- pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.
- Active Comparator: Artemether-lumefantrine
- artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.
Clinical Trial Outcome Measures
Primary Measures
- PCR-corrected adequate clinical and parasitological response (ACPR)
- Time Frame: day 28 after initial dose
Secondary Measures
- PCR-corrected adequate clinical and parasitological response (ACPR)
- Time Frame: day 42 after initial dose
- crude adequate clinical and parasitological response (ACPR)
- Time Frame: day 28, day 42 after initial dose
- parasite clearance time
- Time Frame: up to 7 days after initial dose
- gametocyte clearance time
- Time Frame: up to 7 days after initial dose
- transmission potential to mosquitos
- Time Frame: day 7 after initial dose
Participating in This Clinical Trial
Inclusion Criteria
- Children between 6 months and 12 years old, with a body weight of ≥5 kg; – Living in the catchment area of the study (within a radius of ~10 km from St. Jude's Clinic, Mbita, Kenya); – Having microscopically confirmed P. falciparum mono-infection (asexual parasite density 1,000-200,000 µL-1). Exclusion Criteria:
- Signs and symptoms of severe malaria (according to WHO criteria for severe malaria, (WHO 2012)) or any other severe illness necessitating parenteral treatment; – Mixed Plasmodium infection; – Clinically suspected (oedema, jaundice and/or ascites) or reported hepatic and/or renal impairment (any cause, as reported by parents/guardians and/or evident from medical history); – Having anaemia with an Hb <6 g/dL; – Evidence of severe malnutrition (severe wasting: z-score weight for age <-3 and severe stunting: z-score height for age <-3 (WHO 2009b)); – Having received anti-malarial therapy in the previous two weeks; – Known history of hypersensitivity, allergic or adverse reactions to artesunate, artemether-lumefantrine or other artemisinins; – Participating in other anti-malarial drug intervention studies; – Previous participation in the PAAL study, e.g. in the previous transmission season (each individual child can only take part in this study once); – Not being available for follow-up.
Gender Eligibility: All
Minimum Age: 6 Months
Maximum Age: 12 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Royal Tropical Institute
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Patrick Sawa, MD, PhD, Principal Investigator, International Centre of Insect Physiology and Ecology (ICIPE)
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.